The Introduction

    A biotech incubator for major pharmaceutical companies


    • U.S. and Australian institutional research collaborations
    • Two clinical-stage candidates, one currently pre-clinical
    • Current focus on the improvement and extension of lives of prostate cancer patients with metastatic disease

    Filamon is commencing with three drug candidates: FLM-JG1 & FLM-c2 and FLM- BT2

    All three involve ground-breaking discoveries that have eluded major pharma companies.

    Our strategy is considerably de-risked with FLM-c2 already in the clinic and FLM-JG1 a repurposed drug with global marketing approval.

    Together, Filamon believes all three technologies hold the key to halting the march of a cancer that kills an estimated 300,00 men globally each year.